154.36
price down icon1.81%   -2.85
after-market アフターアワーズ: 154.58 0.22 +0.14%
loading
前日終値:
$157.21
開ける:
$156.59
24時間の取引高:
1.39M
Relative Volume:
1.19
時価総額:
$15.52B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
33.07
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
-0.92%
1か月 パフォーマンス:
+15.84%
6か月 パフォーマンス:
+11.81%
1年 パフォーマンス:
+25.68%
1日の値動き範囲:
Value
$153.27
$156.88
1週間の範囲:
Value
$153.27
$162.39
52週間の値動き範囲:
Value
$117.59
$162.39

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1105)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-05-05
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
154.36 15.81B 2.86B 478.60M 748.70M 4.6676
TAK icon
TAK
Takeda Pharmaceutical Co Adr
16.58 52.36B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
9.20 40.62B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
34.07 39.63B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
78.92 32.58B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
566.80 24.07B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
06:34 AM

New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st

06:34 AM
pulisher
04:31 AM

Morgan Stanley lists Rule 144 sale of NBIX-linked shares | NBIX SEC FilingForm 144 - Stock Titan

04:31 AM
pulisher
04:30 AM

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill

04:30 AM
pulisher
04:28 AM

New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter

04:28 AM
pulisher
03:28 AM

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews

03:28 AM
pulisher
12:33 PM

Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo

12:33 PM
pulisher
May 18, 2026

Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK

May 18, 2026
pulisher
May 18, 2026

Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com

May 18, 2026
pulisher
May 18, 2026

Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo

May 18, 2026
pulisher
May 18, 2026

Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia

May 18, 2026
pulisher
May 18, 2026

Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules - PR Newswire

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart

May 18, 2026
pulisher
May 18, 2026

Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart

May 18, 2026
pulisher
May 18, 2026

Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com

May 18, 2026
pulisher
May 18, 2026

Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView

May 18, 2026
pulisher
May 18, 2026

Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - ChartMill

May 18, 2026
pulisher
May 18, 2026

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - Yahoo Finance

May 18, 2026
pulisher
May 18, 2026

Neurocrine Biosciences (NBIX) Stock Analysis: Strong Buy Ratings and 20% Upside Potential - DirectorsTalk Interviews

May 18, 2026
pulisher
May 18, 2026

Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN

May 18, 2026
pulisher
May 17, 2026

Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien - AD HOC NEWS

May 17, 2026
pulisher
May 15, 2026

[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan

May 15, 2026
pulisher
May 15, 2026

NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

May 15, 2026
pulisher
May 14, 2026

Neurocrine Biosciences director Norwalk sells $590,601 in stock By Investing.com - Investing.com Canada

May 14, 2026
pulisher
May 14, 2026

Neurocrine Biosciences director Norwalk sells $590,601 in stock - Investing.com

May 14, 2026
pulisher
May 14, 2026

Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan - Stock Titan

May 14, 2026
pulisher
May 14, 2026

Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position - AD HOC NEWS

May 14, 2026
pulisher
May 13, 2026

Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN

May 13, 2026
pulisher
May 13, 2026

Neurocrine Biosciences stock hits all-time high at 160.31 USD By Investing.com - Investing.com Nigeria

May 13, 2026
pulisher
May 13, 2026

A Look at Neurocrine Biosciences Inc (NBIX) After 3.5% Gain -- G - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com

May 13, 2026
pulisher
May 13, 2026

Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates - simplywall.st

May 13, 2026
pulisher
May 12, 2026

Number of shareholders of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView

May 12, 2026
pulisher
May 12, 2026

Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue - AD HOC NEWS

May 12, 2026
pulisher
May 12, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity - ChartMill

May 12, 2026
pulisher
May 12, 2026

Neurocrine stock soars 61% after InvestingPro Fair Value signal By Investing.com - Investing.com Canada

May 12, 2026
pulisher
May 11, 2026

Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st

May 11, 2026
pulisher
May 11, 2026

Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations By Investing.com - Investing.com South Africa

May 11, 2026
pulisher
May 11, 2026

Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations - Investing.com

May 11, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
RGC RGC
$27.00
price down icon 2.84%
$16.17
price down icon 2.00%
RDY RDY
$13.45
price down icon 1.10%
$19.80
price down icon 0.65%
$566.80
price down icon 0.03%
大文字化:     |  ボリューム (24 時間):